ReviewStroke2021
Cancer and Embolic Stroke of Undetermined Source.
Review in Stroke, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antithrombotic therapy for secondary stroke prevention in patients with cancer: a systematic review and network meta-analysis.European journal of clinical pharmacology · 2025Pooled it
- History of Cancer and Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Clinical Trial.Journal of the American Heart Association · 2025Trial
- Article
- Diagnosis of Occult Cancer Using Fluorodeoxyglucose Positron Emission Tomography/CT in Cryptogenic Stroke Patients.Internal medicine (Tokyo, Japan) · 2026Article
- Molecular heterogeneity in human stroke - What can we learn from the peripheral blood transcriptome?Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026Review
- Development and Validation of the Predicting Risk of Ischemic Stroke in Malignancy Estimation Tool.Journal of the American Heart Association · 2026Article
- Risk Factors for Adverse Outcomes in Cancer Patients With Sepsis.Journal of clinical medicine research · 2026Article
- The role of computed tomography in thrombus characterization: Insights from a stroke cohort of known and unknown etiology.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Tissue factor activity and 1-year mortality in patients with active cancer and acute ischemic stroke: findings from the SCAN study.Research and practice in thrombosis and haemostasis · 2026Article
- Predicting cancer aetiology in patients with stroke using brain imaging alone.BMJ neurology open · 2026Article
- Exploratory assessment of bleeding risk associated with concurrent use of Anti-VEGF agents and anticoagulants in oncology.Frontiers in pharmacology · 2026Article
- Cryptogenic stroke: definitions and management.Hematology. American Society of Hematology. Education Program · 2025Review
- Outcomes of patients with in-hospital stroke with and without active cancer.Journal of thrombosis and thrombolysis · 2025Article
- Atrial fibrillation and ischemic stroke in cancer: the latest scientific evidence, current management, and future directions.Journal of thrombosis and thrombolysis · 2025Review
- Review
- Anticoagulant Usage and Risk of Thromboembolic Events After Ischemic Stroke in Adults With Cancer.Neurology · 2025Article
- The B-SCancers · 2025Article
- Lipid homeostasis dysregulation in oral cancer drives metabolic reprogramming and offers novel diagnostic and therapeutic opportunities.Discover oncology · 2025Review
- Long-Term Outcomes and Predictors in Cancer-Related Stroke Using the Linked Data Set.Journal of the American Heart Association · 2025Article
- Machine learning identification of key genes in cardioembolic stroke and atherosclerosis: their association with pan-cancer and immune cells.European journal of medical research · 2025Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
One-quarter to one-third of ischemic strokes have no established mechanism after standard diagnostic evaluation and are classified as embolic stroke of undetermined source (ESUS). Failure of randomized trials to demonstrate a benefit of direct oral anticoagulants over aspirin for the treatment of ESUS as a single homogeneous entity has led to renewed interest by stroke experts to divide ESUS into subgroups. Emerging data suggest that active cancer, which is present in 5% to 10% of patients with ESUS, is a distinct and important subgroup of ESUS with unique clinical characteristics, underlying pathophysiologies, and treatment and prognostic considerations. Furthermore, the prevalence of cancer-related ESUS is expected to increase as patients with cancer, even those with distant metastases, survive longer due to improvements in cancer treatments. In this topical review, we examine the epidemiological link between ESUS and cancer, the clinical features and potential mechanistic underpinnings of ESUS with cancer (with a focus on novel biomarkers and their relationship to recurrent stroke and other thromboembolic events), and the potential treatment strategies for cancer-related ESUS. We include a critical appraisal of existing data and ongoing or planned clinical trials of different antithrombotic approaches. As cancer-related ESUS is a dynamic disease with variable course, we recommend close collaboration between neurologists and oncologists to develop individualized management plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.